Lancashire and South Cumbria
Formulary
2 Cardiovascular system
02-02-03 Aldosterone antagonists
Spironolactone
Formulary
Tablets 25mg, 50mg, 100mg
Heart failure
MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article
NG106: Chronic heart failure in adults: diagnosis and management
Eplerenone
Formulary
Tablets 25mg, 50mg
Heart failure
NG106: Chronic heart failure in adults: diagnosis and management
Finerenone
Formulary
Please see chapter 06.01.05
Links
Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**
Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
LSCMMG: Atrial Fibrillation
LSCMMG: Heart Failure - Primary Care Guideline for the Use of SGLT-2 Inhibitors in Reduced Ejection Fraction Heart Failure
LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
LSCMMG: Low Molecular Weight Heparins (LMWHs) Summary Prescribing Guide
MHRA Drug Safety Update Dec 2016: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
MHRA Drug Safety Update Feb 2016: https://www.gov.uk/drug-safety-update/spironolactone-and-renin-angiotensin-system-drugs-in-heart-failure-risk-of-potentially-fatal-hyperkalaemia
MHRA Drug Safety Update Feb 2016: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article
MHRA Drug Safety Update: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
MHRA: Clopidogrel and proton pump inhibitors: interaction—updated advice
MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—clarification, December 2016
MHRA: Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia—February 2016 article
NG 185 - Acute coronary syndromes
NG 196 - Atrial fibrillation: diagnosis and management
NG106: Chronic heart failure in adults: diagnosis and management
NG106: Chronic heart failure in adults: diagnosis and management
NICE NG106: Chronic heart failure in adults: diagnosis and management
NICE NG136: Hypertension in adults: diagnosis and management
NICE NG187: Acute heart failure: diagnosis and management
NICE NG203: Chronic kidney disease: assessment and management
NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
NICE TA877 Finerenone for treating chronic kidney disease in type 2 diabetes
Key
Full Site